Live tape
Top 8, mentions 7d16,112MSFT3,148 mentions▲ +0.09GOOGL2,249 mentions▲ +0.05AAPL2,177 mentions▲ +0.07META2,123 mentions▲ +0.04SNDK1,889 mentions▲ +0.07NVDA1,633 mentions▲ +0.07SPCX1,612 mentions▲ +0.06AMZN1,281 mentions▲ +0.09

Equity · Healthcare

BMRN

BioMarin Pharmaceutical Inc. · NasdaqGS

$62.08 +3.03% 1D Finazon · prior-day close · Jul 28, 2026
Price · Chart Chart by TradingView
Track this symbol on TradingView

The chart above plots the price of BMRN over the range selected — one day to the full history — drawn by TradingView from their own data. Our own licensed end-of-day series holds 61 sessions over that window: $55.00 on 4 May 2026 through $62.08 on 28 July 2026. Finazon · prior-day close.

Market cap $12.0B
P/E (TTM) 24.3
52-week range $49.67 – $65.00
Avg volume 413.4K

Finazon · prior-day close · valuation computed from SEC EDGAR filings · as of Jul 29, 2026

BMRN insider trades

SEC Form 4 · last 90 days · newest reported trade 2 Jun 2026
Open-market buys 0
Open-market sells 1
Net sold $177K
Non-trade filings 10
Date Insider Type Shares Value
07 May 2026 Friberg Gregory R EVP, Chief R&D Officer Sell 3,281 $177K
Compensation mechanics (10 filings)

Compensation mechanics Share grants, option exercises, tax withholding and transfers. They reach the same Form 4 as a trade, but they are not the insider buying or selling on the open market, so no purchase or sale value applies to them.

Date Insider Type Shares Value
02 Jun 2026 ANDERSON ELIZABETH M Director Award 7,490
02 Jun 2026 Bodem Barbara W. Director Award 7,490
02 Jun 2026 CLARK IAN T Director Award 7,490
02 Jun 2026 Dere Willard H Director Award 7,490
02 Jun 2026 Enyedy Mark J Director Award 7,490
02 Jun 2026 HOMBACH ROBERT J. Director Award 7,490
02 Jun 2026 Ho Maykin Director Award 7,490
02 Jun 2026 Walbert Timothy P Director Award 7,490
02 Jun 2026 Countouriotis Athena Director Award 7,490
20 May 2026 Hubbard Cristin EVP, Chief Commercial Officer Tax withheld 2,318 $116K

BMRN reported financials

SEC EDGAR XBRL

BMRN reported revenue of $3.2B for the fiscal year ended 31 Dec 2025. Net income over the same period was $348.9M.

Figure Reported Period
Revenue $3.2B 31 Dec 2025 fiscal year
Net income $348.9M 31 Dec 2025 fiscal year
Diluted EPS $1.80 31 Dec 2025 fiscal year
Total assets $8.6B 31 Mar 2026 at period end
Total equity $6.2B 31 Mar 2026 at period end

Source: SEC EDGAR XBRL company facts · latest period ended 31 Mar 2026

BMRN earnings

SEC EDGAR
Date Period EPS Revenue
31 Mar 2026 Q1 2026 $0.54 —
31 Dec 2025 FY 2025 $1.80 —
30 Sep 2025 Q3 2025 $-0.16 —
30 Jun 2025 Q2 2025 $1.23 —

Reported figures & scheduled dates · SEC EDGAR filings

BMRN institutional holders

SEC Form 13F

13 of the 45 institutional funds we track reported a BMRN position for the quarter ended 31 Mar 2026 — a combined $1.5B; the latest of those filings landed 15 May 2026.

Fund Action Shares Value
AQR Capital Management Held (±25%) +14.8% shares 7,676,541 $429.3M
Viking Global Investors Held (±25%) +17.0% shares 7,062,077 $398.9M
Citadel Advisors Added +230.7% shares 4,512,634 $254.9M
Millennium Management Held (±25%) −0.9% shares 3,010,308 $170.1M
Balyasny Asset Management New position 1,362,752 $77.0M
Point72 Asset Management Added +173.3% shares 1,199,206 $67.7M
Renaissance Technologies Held (±25%) −22.6% shares 1,024,871 $57.9M
Man Group Held (±25%) −14.3% shares 309,659 $17.5M
D. E. Shaw & Co. Trimmed −71.9% shares 282,460 $16.0M
Bridgewater Associates Held (±25%) −10.0% shares 206,911 $11.7M

Source: SEC EDGAR 13F filings

BMRN fails-to-deliver

SEC CNS data

On 30 Jun 2026, 23 shares of BMRN failed to deliver (about $1K) — the latest of 2 consecutive trading days with recorded fails.

Settlement date Shares failed Notional % of shares out
30 Jun 2026 23 $1K <0.001%
29 Jun 2026 1,700 $100K 0.001%

Source: SEC fails-to-deliver (CNS) data